NCT02172976View on ClinicalTrials.gov

Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

January 31, 2020

Study Completion Date

May 31, 2020

Conditions

Resectable Prancreas Carcinoma

Interventions

DRUG

Gemcitabine

DRUG

Oxaliplatin

DRUG

5-Fluorouracil

DRUG

Irinotecan

DRUG

Natriumfolinate

Trial Locations (1)

60488

Institute of Clinical Cancer Research (IKF), UCT - University Cancer Center, Frankfurt, Germany, Frankfurt

All Listed Sponsors

lead

Krankenhaus Nordwest

OTHER

NCT02172976 - Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma | Biotech Hunter | Biotech Hunter